MRD News and Press, Memorial Resource Development Corp.

EDMONTON, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX: MRD), announced today a correction to its press release entitled "Melcor Developments announces results for 2023, declares $0.11 per share dividend" which was issued on March 13, 2024 (the "Initial Press Release"...

EDMONTON, Alberta, March 13, 2024 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the fourth quarter and year ended December 31, 2023. The annual Management Discussion & Analysis (M...

EDMONTON, Alberta, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the third quarter and nine months ended September 30, 2023. The third quarter Management Discussion &...

EDMONTON, Alberta, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the second quarter and six months ended June 30, 2023. Revenue was down 3% to $101.32 million year-...

EDMONTON, Alberta, June 05, 2023 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX:MRD), an Alberta-based real estate development and asset management company, announced today that the Toronto Stock Exchange has accepted its notice of intention to make a normal course issuer bid through the facil...

EDMONTON, Alberta, May 10, 2023 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the quarter ended March 31, 2023. Revenue was down $36.08 million or 32% compared to Q1-2022. Revenu...

EDMONTON, Alberta, April 26, 2023 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, announced the results of its annual general meeting (AGM), held today. A total of 25,484,340 shares were voted in person or by proxy, r...

After receiving minutes from its End-of-Phase 2 meeting with the FDA, Kronos Bio, Inc. (KRON) announced that it will initiate a Phase 3 trial for entospletinib in mid-2021 in patients newly diagnosed with NPM1-mutated acute myeloid leukemia (AML).The primary endpoint will be measura...

Actionable Conclusions (1-10): Analysts Estimated 12.79% To 23.9% Net Gains For Ten Top International Dividend Aristocrat Dogs To December 2020 Four of these ten top Kiplinger world's most reliable dividend stocks by yield were among the top ten gainers for the coming year based on a...

Actionable Conclusions (1-10): Analysts Estimated 13.68% To 31.38% Net Gains For Ten Top International Dividend Aristocrat Dogs Into 2020 Four of these ten top Kiplinger most reliable dividend stocks by yield were among the top ten gainers for the coming year based on analyst one-year ...